Current treatments for chronic hepatitis B are suboptimal. In the search for improved therapies, we compared the efficacy and safety of pegylated interferon alfa plus lamivudine, pegylated interferon ...

Please provide your email address to receive an email when new articles are posted on . The cumulative probability of functional cure was 14.53% at a mean age of 25.75 years. The annual cure rate was ...

Please provide your email address to receive an email when new articles are posted on . The combination of hepatitis B surface antigen and hepatitis B virus DNA levels at week 12 identifies hepatitis ...

Much of the liver injury in HBV infection reflects host immune response rather than a direct cytopathic effect of the virus. During the course of chronic HBV infection, biochemical dysfunction may be ...

Available treatments for hepatitis B e antigen (HBeAg)–negative chronic hepatitis B are associated with poor sustained responses. As a result, nucleoside and nucleotide analogues are typically ...

HBsAg decline at week 24 and baseline HBsAg levels are better predictors of functional cure than novel virologic markers, while on-treatment HBV RNA and HBeAg levels and dynamic changes are the most ...

Chronic hepatitis B virus (HBV) is the most common cause of liver disease throughout the world. [1] More than 300 million persons are currently estimated to be infected with HBV worldwide. The highest ...

In HepG2.117 cells, ALG-001075 achieved HBV DNA EC50 0.64 nM, outperforming canocapavir (5.8 nM) and neracorvir (24 nM) with ...

Two cross-sectional, one validation cohort, and meta-analyses were used to explore the relationship between HBV replication and liver inflammation. Spearman analysis, multiple linear regression, and ...